Clinical Trial Results:
Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant Pathologies
Summary
|
|
EudraCT number |
2016-000316-15 |
Trial protocol |
PL |
Global end of trial date |
12 Jun 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Oct 2019
|
First version publication date |
12 Oct 2019
|
Other versions |
|
Summary report(s) |
523079.01.114 Summary of results for Eudra CT database V1.0 2019_09_25 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
523079.01.114
|
||
Additional study identifiers
|
|||
ISRCTN number |
ISRCTN83227991 | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Dr. Willmar Schwabe GmbH & Co. KG
|
||
Sponsor organisation address |
Willmar-Schwabe-Str. 4, Karlsruhe, Germany, 76227
|
||
Public contact |
Head Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 0049 7214005573,
|
||
Scientific contact |
Head Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, 0049 7214005573,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
23 Jul 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
12 Jun 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Jun 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
• To explore whether causes, risk factors, chronicity of vertigo and accompanying features influence the treatment effect of EGb 761® in terms of improvement and response rates
• To identify groups of patients that benefit most of EGb 761®
|
||
Protection of trial subjects |
Possibility to withdraw informed consent. Monitoring of adverse events and laboratory parameters.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
28 Oct 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 206
|
||
Worldwide total number of subjects |
206
|
||
EEA total number of subjects |
206
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
160
|
||
From 65 to 84 years |
46
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Subjects were recruited in twelve investigational sites in Poland. | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Twenty seven patients did not receive the investigational product since they were classified as screening failures. | ||||||||||||||||||||||||
Pre-assignment period milestones
|
|||||||||||||||||||||||||
Number of subjects started |
206 | ||||||||||||||||||||||||
Number of subjects completed |
179 | ||||||||||||||||||||||||
Pre-assignment subject non-completion reasons
|
|||||||||||||||||||||||||
Reason: Number of subjects |
Screening Failures: 27 | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Treatment period (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
No
|
||||||||||||||||||||||||
Arm title
|
Baseline | ||||||||||||||||||||||||
Arm description |
Baseline before starting treatment with EGb 761® | ||||||||||||||||||||||||
Arm type |
Baseline | ||||||||||||||||||||||||
Investigational medicinal product name |
No investigational medicinal product assigned in this arm
|
||||||||||||||||||||||||
Arm title
|
EGb 761® | ||||||||||||||||||||||||
Arm description |
Investigational medical product containing EGb 761®, two film-coated tablets of 120 mg Ginkgo biloba extract | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
EGb 761®
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
1 film-coated tablet 2 times per day for 12 consecutive weeks.
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment period (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In total, 179 subjects received the investigational treatment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same. Justification: Some patients were not included into the analysis set due to drop out without havinbg tretament |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Full Analysis Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Full analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The full analysis set (FAS) includes all patients who took EGb 761® treatment and have at least one value of one of the most important variables to describe treatment effects assessed after baseline.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety Evaluation Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The safety evaluable set (SES) comprises all patients having taken at least one tablet of EGb 761®.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline
|
||
Reporting group description |
Baseline before starting treatment with EGb 761® | ||
Reporting group title |
EGb 761®
|
||
Reporting group description |
Investigational medical product containing EGb 761®, two film-coated tablets of 120 mg Ginkgo biloba extract | ||
Subject analysis set title |
Full Analysis Set
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
The full analysis set (FAS) includes all patients who took EGb 761® treatment and have at least one value of one of the most important variables to describe treatment effects assessed after baseline.
|
||
Subject analysis set title |
Safety Evaluation Set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
The safety evaluable set (SES) comprises all patients having taken at least one tablet of EGb 761®.
|
|
|||||||||||||
End point title |
Primary end point [1] | ||||||||||||
End point description |
This document in its section "End points" specifies commercially confidential information of Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe referred to in Article 81 Section (4) b) Regulation (EU) 536/2014 that is a trade secret and released by the holder for purposes of Regulation (EU) 536/2014 only under the condition of confidence. Trade secrets may not - even in part - be published or released to third parties other than to competent authorities without express permission of the trade secret holder.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Week 0 - week 12
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: See document for a complete description of the statistical methods and results. There were no primary end points defined for analysis. Because at least one primary end point is required to be entered into the database, the outcome variable presented here have been chosen to this purpose. Statistical analyses were conducted descriptively for all end points. Please refer to the attached summary of results for details. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
15 weeks
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Non-serious adverse events occurred in 33 patients. However, no incidence of preferred terms of adverse events was higher than the threshold of 5%.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
After risk phase
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
After risk phase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Between begin of study and begin of 1st study period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Before Tretament | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment with EGb 761® 240 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Study Drug | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No adverse events (AE) with an incidence higher than the threshold of 5% occurred during the trial. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |